-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下： IP公司2026年第一季業績喜憂參半。調整後的營業利潤為8,100萬美元，較上年同期略有成長；但淨銷售額為59.7億美元，較上季下降0.6%；經調整後的EBITDA為6.77億美元，較上季及年比均下降。各業務部門的業績呈現分化趨勢：北美產品銷售業務（PS NA）的營業利潤為2.48億美元，年增74.6%，但環比下降22.3%；而歐洲、中東和非洲產品銷售業務（PS EMEA）儘管銷量增長，但仍持續虧損5100萬美元。我們認為，管理層計劃在12-15個月內剝離EMEA業務，這代表著重大的策略轉型。全年經調整後的EBITDA預期為32億至35億美元，反映了持續的轉型成本和營運挑戰。執行長西爾弗內爾承認可靠性問題持續存在，並強調成本和現金流管理是改善工作的關鍵，相關改進工作仍在進行中。我們認為，隨著公司建立兩個獨立實體，轉型過程中的執行風險可能會持續影響績效。
Related Articles
Research
Research Alert: The Clorox Company Beats Estimates Driven By Household And International
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CLX reported Q3 FY 26 net sales of $1.67B, flat Y/Y with organic sales down 1%, while adj. EPS of $1.64 grew 13% and beat consensus by $0.10. Gross margin contracted 140 bps to 43.2% due to elevated manufacturing costs and unfavorable mix, though disciplined expense management supported earnings. Mixed segment performance showed Household and International delivering growth of 3% and 8%, respectively, while Lifestyle declined 9% on lower consumption and inventory adjustments. Management updated FY 26 guidance expecting net sales to decline ~6% with organic sales down ~9%, including a 7.5%-pt ERP headwind. Adj. EPS guidance of $5.45-$5.65 represents a 27%-29% decline, with gross margin expected to contract 250-300 bps from GOJO inventory step-up and elevated energy costs. The April 1 GOJO acquisition expands the health portfolio though near-term integration costs pressure results. We believe the completed $580M digital transformation positions CLX for long-term operational improvements despite macro headwinds.
$CLX
Research
Research Alert: Rivn: Q1 Eps Ahead Of Consensus; 2026 Guidance Unchanged
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Rivian (RIVN) posted Q1 adjusted EPS of -$0.55 vs. -$0.41, ahead of the -$0.60 consensus. Revenue rose 11% to $1.38B ($10M ahead of consensus) on a 20% increase in total vehicle sales to 10,365 units, augmented by a 49% Y/Y increase in software and services revenue to $473M. RIVN's gross margin contracted 800 bps to 8.6%, but was ahead of the 8.4% consensus. The quarter's financial results reflect the company's strategic pivot toward broader market accessibility with the R2, though at the cost of near-term profitability. RIVN maintained prior 2026 guidance for adjusted EBITDA, vehicle deliveries, and capex. The company ended Q1 with cash of $4.8B, down from $6.1B at year-end 2025. Shares are trading 1% higher in after-hours trading. RIVN's Q1 earnings were ahead of expectations, although cash burn remains a key concern, with free cash flow deteriorating, driven by increased operating expenses and working capital consumption. Execution risks remain high given challenging demand facing the broader EV industry.
$RiVN
Australia
Tanger Q1 Core FFO, Revenue Rise; 2026 Guidance Increased
Tanger (SKT) reported Q1 core funds from operations late Thursday of $0.59 per diluted share, up from $0.53 a year earlier.Analysts polled by FactSet expected $0.58.Revenue in the three months ended March 31 rose to $150.4 million from $135.4 million a year earlier.Analysts surveyed by FactSet expected $142.9 million.The company raised 2026 FFO guidance to $2.42 to $2.50 per diluted share from $2.41 to $2.49.Analysts polled by FactSet expect $2.47.Tanger shares fell 2.3% in after-hours trading.
$SKT